SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-106304
Filing Date
2021-04-05
Accepted
2021-04-05 16:01:35
Documents
13
Period of Report
2021-03-31
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d40312d8k.htm   iXBRL 8-K 29643
2 EX-16.1 d40312dex161.htm EX-16.1 3243
  Complete submission text file 0001193125-21-106304.txt   158604

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fstx-20210331.xsd EX-101.SCH 3086
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fstx-20210331_lab.xml EX-101.LAB 18053
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fstx-20210331_pre.xml EX-101.PRE 11391
6 EXTRACTED XBRL INSTANCE DOCUMENT d40312d8k_htm.xml XML 3432
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Filer) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37718 | Film No.: 21805289
SIC: 2834 Pharmaceutical Preparations